Page 2 - Pricing Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Objectives To evaluate the added benefit and revenues of oncology drugs, explore their association, and investigate potential discrepancies between added benefit and revenues across different approval pathways of the European Medicines Agency (EMA). Design Retrospective cohort study. Setting Oncology drugs and their indications approved by the EMA between 1995 and 2020. Main outcome measures Added benefit was evaluated using ratings published by seven organisations: health technology assessment agencies from the United States, France, Germany, and Italy, two medical oncology societies, and a d...

Insurers need to sort out their data swamps by creating data lake houses or risk being left behind in the “data arms race”, experts have warned.

ENGINE X will be a separate entity, a company source tells Ship & Bunker. ENGINE was originally part of Navig8 Group before being spun off.

Upon integration, the Lumesis DIVER product suite will provide additional municipal asset class workflow, analytics related to price transparency, and regulatory-related solutions to SOLVE'S Market Data Platform.

The tool provides summaries of outstanding debt, maturity profiles, and debt service schedules for the entire public finance market and is an outgrowth of the company's legacy Debt Maps.